Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 17/20 | 0.52 |
| ▸ | MERTK | Q12866 | 17/20 | 0.52 |
| ▸ | FLT3 | P36888 | 13/20 | 0.52 |
| ▸ | GAS6 | Q14393 | 13/20 | 0.52 |
| ▸ | AXL | P30530 | 5/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13421139 | 1.00 | TYRO3 (0.52) | TYRO3MERTKFLT3GAS6AXL | |
| SCHEMBL3450061 | 1.00 | TYRO3 (0.52) | TYRO3MERTKFLT3GAS6AXL | |
| SCHEMBL3449062 | 0.88 | CSNK2A1 (0.53) | TYRO3MERTKFLT3GAS6AXL | |
| SCHEMBL13311124 | 0.88 | CSNK2A1 (0.53) | TYRO3MERTKFLT3GAS6AXL | |
| SCHEMBL13420488 | 0.88 | CSNK2A1 (0.53) | TYRO3MERTKFLT3GAS6AXL | |
| SCHEMBL3448690 | 0.85 | SYK (0.55) | TYRO3MERTKAXLEGFRERBB2 | |
| SCHEMBL3450053 | 0.83 | TYRO3 (0.46) | TYRO3MERTKFLT3GAS6AXL | |
| SCHEMBL3450052 | 0.83 | TYRO3 (0.46) | TYRO3MERTKFLT3GAS6AXL | |
| SCHEMBL3449012 | 0.83 | FLT3 (0.48) | TYRO3MERTKFLT3GAS6EGFR | |
| SCHEMBL3449008 | 0.83 | FLT3 (0.48) | TYRO3MERTKFLT3GAS6EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | TYRO3 2798/4885MERTK 1743/4885FLT3 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.